SCHEMBL5363904

SCHEMBL5363904

CC(C)(C)OC(=O)N1CCN(c2cccc3c2Nc2ccccc2NC3=O)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 4/20 0.58
SMARCA2 P51531 1/20 0.47
SMARCA4 P51532 1/20 0.47
PBRM1 Q86U86 1/20 0.47
PDK2 Q15119 1/20 0.46
AKT1 P31749 1/20 0.46
CKS1B P61024 2/20 0.44
SKP1 P63208 2/20 0.44
SKP2 Q13309 2/20 0.44
MAPK1 P28482 1/20 0.44
GPR119 Q8TDV5 2/20 0.42
CRBN Q96SW2 1/20 0.42
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
NAMPT P43490 1/20 0.41
PDK4 Q16654 1/20 0.41
PARP1 P09874 1/20 0.41
TNKS2 Q9H2K2 1/20 0.41
PARP2 Q9UGN5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5945010 0.83 BACE1 (0.50) BACE1SMARCA2SMARCA4PBRM1PDK2
SCHEMBL5357287 0.81 BACE1 (0.53) BACE1SMARCA2SMARCA4PBRM1PDK2
SCHEMBL13244107 0.81 BACE1 (0.46) BACE1SMARCA2SMARCA4PBRM1PDK2
SCHEMBL20818663 0.77 CKS1B (0.58) BACE1SMARCA2SMARCA4PBRM1PDK2
SCHEMBL8265823 0.77 BACE1 (0.47) BACE1SMARCA2SMARCA4PBRM1PDK2
SCHEMBL30273928 0.77 PARP1 (0.51) BACE1SMARCA2SMARCA4PBRM1PDK2
SCHEMBL20129629 0.76 CRBN (0.53) BACE1SMARCA2SMARCA4PBRM1PDK2
SCHEMBL13244108 0.76 CRBN (0.53) BACE1SMARCA2SMARCA4PBRM1PDK2
SCHEMBL31727176 0.76 BACE1 (0.48) BACE1SMARCA2SMARCA4PBRM1PDK2
SCHEMBL5356816 0.76 HTR7 (0.53) ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-20060154914-A1 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC 2006-07-13 US disclosed
WO-2006061126-A2 DIBENZOXAZEPINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154914-A1 Dibenzoxazepinone derivatives and uses thereof HTR6, BDKRB1, HTR7 BACE1 2599/4885SMARCA2 1415/4885SMARCA4 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.